Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

•Allogeneic blood or marrow transplantation (alloBMT) with post-transplantation cyclophosphamide (PTCy) in patients with acute lymphoblastic leukemia (ALL) age ≥55 years yielded a 5-year overall survival (OS) of 49%.•Grade III-IV acute graft-versus-host disease (GVHD) (3%) and chronic GVHD of any severity (13%) were limited with PTCy.•Patients in second remission, with T-ALL, and receiving myeloablative conditioning fared poorly.•The 5-year OS as 65% in patients with B-ALL who underwent alloBMT in first complete remission with reduced-intensity conditioning.